European Society of Toxicology in Vitro ESTIV’s Post

I have created a FREE laboratory course for university students. Should be useful in showing students the power of GC-MS in drug identification. See https://lnkd.in/gC88AiVn Also see my seminar on using the NIST hybrid search and other "spectraless" databases such ad ChemSpider and CAS Registry (SciFinder) for several powerful approaches for the identification of illicit drugs using GC-MS! https://lnkd.in/gFH_MVz8

According to 2023 data, Gator Bio's Small Molecule Analytical Probes (SMAPs) are very popular. I think one of the reasons is the growth of research into peptide drugs, such as peptibody. Just like ADCs, small peptides are conjugated to antibodies rather than small molecules. Its advantages are high specificity, versatility, small size, and customizability. As a new type of antibody drug, Peptibody has broad application prospects. In the future, with the continuous maturity of technology, Peptibody drugs are expected to become one of the important innovations in the field of biomedicine. We’ll need more products like SMAP and SA-XT. #ADC #Peptibody #SMAP #BLI #Antibody #Conjugation #Analytical https://lnkd.in/gMAqR_zX

Need a simple and reliable method for assessing drug-induced mitochondrial toxicity and gaining insights into toxicity modes? Read our poster to learn how to improve your drug candidate discovery with the Seahorse XF Mito Tox Assay kit. Find out more: https://lnkd.in/dGgs964U

2 days left to register! Can't attend live? Register and we'll send a copy of the slides and recording. Please submit your questions in the comments and the team will answer in the live Q&A session. Manoj Misra, Ph.D. Jeffrey Bemis Sean Oh #webinar #microflow #toxicology

I am so pleased today to be able to point to this publication detailing our use of a versatile differential equation comprising a normal-distribution-modified line for modeling certain analytical data of interest to pharmaceutical development. My sincere thanks to my co-workers Susannah Gaye and Morgan Crawford, professor Scoville of Ursinus College, and lastly to Dennis Peters (1937-2020) to whom this work is dedicated. https://lnkd.in/e9SVydg3 If you've read this post this far, may I ask you to consider the following? Have you ever collected or analyzed any measurement data which were ostensibly linear but sometimes had one or more data points (often at one extreme or another of a given range) which seemed to deviate variably and uncomfortably far away from a linear trend? Be honest--have you ever excluded one or more of those data points so you could do a simple linear regression through only the best looking values, even if a sub-set of the data really does cover the range you need? Certainly expediency has its place. After all, it is undeniably true that "the perfect is the enemy of the good". Still, there are times when a deeper examination of raw data is warranted. If and when such a time arrives for you, please look through this paper and remember that I, like Dr. Peters before me, would be delighted if you reached out. Be well, Lee

📢 Have you heard about the upcoming changes to the ISO 10993 standards? The Business Leaders from #NelsonLabs  recently returned from the 2023 AAMI Biological Evaluation Standards Week meetings. Listen in as our experts discuss the industry trends coming out of these working groups, including a new committee draft that integrates key ISO 14971 concepts, clarification of genotoxicity assessments, a shift toward in vitro thrombogenicity testing, TIR evaluation of cytotoxicity failures, and more. Register or login to listen: https://ow.ly/S5t150PEyaR #Biocompatibility   #ISO10993   #ASTM

Have you heard about the upcoming changes to the ISO 10993 standards?   Business Leaders from Nelson Labs recently returned from the 2023 AAMI Biological Evaluation Standards Week meetings. 🎧Listen in as our experts discuss the industry trends coming out of these working groups, including a new committee draft that integrates key ISO 14971 concepts, clarification of genotoxicity assessments, a shift toward in vitro thrombogenicity testing, TIR evaluation of cytotoxicity failures, and more.   Register or login to listen ➡️ https://lnkd.in/dyC4anRP   #Biocompatibility #ISO10993 #ASTM

Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets. Article from #Chugai explaining the discovery of LUNA18, the compound targeting KRASG12D, now in phase 1. What I like most was the speed at which the compound reached clinic. This is because the hit to candidate step is short - "Once a desired hit is obtained, identifying a clinical compound can be relatively straightforward!! " #krasG12D #KRAS #cyclicpeptides

In a couple of weeks Aranit Harizaj, Jan Van Hauwermeiren en Philip Mathuis will attend Advanced Therapies taking place in London March 19-20 and showcase Trince's gentle non-viral transfection technology. In a nutshell our platform is: ·         Very gentle, leading to high yields. ·         Versatile, we have experience with different cargo (DNA, siRNA, #mRNA, proteins, #CRISPR Cas, #CAR,…) and cell types (#iPSCs, #Tcells, #NKcells, #MSCs,…). ·         Proven to be an excellent tool for bio-imaging. ·         Ideal for screening since we can work with different vessels (flasks, 6 up to 384 well plates). ·         Fast: we can transfect all wells in less than 10 minutes (up to approx. 1M cells/sec) ·         We can transfect suspension and adherent cell lines (without trypsinization). ·         On track to become cGMP approved. We happily answer all your questions during the event, so don't hesitate to book a meeting through the conference app or via [email protected]. #celltherapy #cellengineering #nonviral #celltherapymanufacturing #transfection